Citi analyst Peter Verdult downgraded Genmab to Neutral from Buy.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GMAB:
- Genmab to hold a virtual investor update
- Genmab announces results from multiple clinical trials evaluating epcoritamab
- Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
- Genmab price target raised to DKK 3,450 from DKK 2,900 at JPMorgan
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations